Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Diabetic Macular Edemaand Steroids

Diyabetik MakülaÖdemi ve Steroidler

Pages
50–61
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, a historical evaluation of intravitreal steroid applications is presented in terms of past and present time as well as forthcoming era

📌 3 Key Takeaways

🎯
Objective & Hypothesis:With an increasing trend, the incidence of diabetes among subjects over 20-years old has been reported as 13.7% in Turkey.
📊
Key Findings & Data:In patients with diabetic retinopathy, the frequency of maculopathy that has the major effect on visual loss is reported approximately 10%.
💡
Conclusion & Impact:In this review, a historical evaluation of intravitreal steroid applications is presented in terms of past and present time as well as forthcoming era
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

With an increasing trend, the incidence of diabetes among subjects over 20-years old has been reported as 13.7% in Turkey. Retinopaty is one of the devastating complications of such disease. In patients with diabetic retinopathy, the frequency of maculopathy that has the major effect on visual loss is reported approximately 10%. Intravitreally applicated steroids have been used as an effective headstone in the treatment of diabetic maculopathy during the last decades. In this review, a historical evaluation of intravitreal steroid applications is presented in terms of past and present time as well as forthcoming era

Özet

Türkiye'de diyabet sıklığı, 20 yaş üzeri kişilerde %13.7 olarak bildirilmektedir. Retinopati, bu hastalığın en ağır komplikasyonlarından birisidir. Görme kaybı üzerine ciddi etkisi olan makülopati sıklığı, diyabetik retinopatili olgularda yaklaşık olarak %10 olarak bildirilmektedir. Son yıllarda, intravitreal olarak uygulanan steroidler diyabetik makülopati tedavisinde etkin bir köşe taşı olarak kullanılmaktadır. Bu derlemede, intravitreal steroid uygulamalarının dünü, bugünü ve yarını ışığında bir değerlendirme sunulmaktadır

🔖

Cite This Article

KAYA, M., ÖZTÜRK, T., KOÇAK, N., KAYNAK, S. (2015). Diabetic Macular Edemaand Steroids. Retina-Vitreus, Cilt: 23 - Sayı: 0, 50–61. https://ajindex.com/articles/307907

References (12)

  1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
  2. King H, Aubert RE, Herman WH. Global burden of diabetes,1995-2025 prevalance, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
  3. Blumenkranz, M.S. Optimal current and future treatments for diabetic macular oedema Presented at the Cambridge Ophthalmological Sympo- sium, Cambridge University, 3 September 2009. Eye 2010;24:428-34. TURDEP II 2010: Prof. Dr. İlhan SATMAN ve TURDEP II Çalışma Grubu. http://www.turkendokrin.org/files/file/TURDEP_II_2011.pdf.
  4. Xie XW, Xu L, Wang YX, et al. Prevalence and associated factors of diabetic retinopathy. The Beijing Eye Study 2006. Graefe's Arch. Clin. Ophthalmol 2008;246:1519-26.
  5. Bandello F, Parodi MB, Lanzetta P, et al. Diabetic Macular Edema, Coscas G.(Ed.),Macular Edema, Dev.Ophthalmol, Basel, Karger, 2010;47:73-110.
  6. Augustin A, Loewenstein A, Kuppermann BD. General Pathophysiology. Macular Edema, Ed. G. Coscas, Karger, 2010:10-26.
  7. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;5:920-7.
  8. Ozkiris A, Evereklioglu C, Erkiliç K, et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004;14:543-9.
  9. Jonas JB, Degenring RF, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-60.
  10. Audren F, Erginay A, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol Scand 2006;84:624-30.
  11. Jonas JB, Kamppeter BA, Harder B, et al. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-7.
  12. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double- masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113:1533-8. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photoco- agulation for diabetic macular edema. Ophthalmology 2008;115:1447-9. Diabetic Retinopathy Clinical Research Network, Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial compa- ring foca